Real-world Data on Immunotherapy Combined with Chemotherapy in Elderly Patients with Extensive-stage Small Cell Lung Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2025 Mar 15

PMID 40087602

Authors

Ke Zhao

Shuangqing Lu

Jiling Niu

Hui Zhu

Yaru Tian

Jinming Yu

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapy combined with chemotherapy has shown good results in the treatment of extensive-stage small cell lung cancer (ES-SCLC), but there are fewer clinical studies on elderly ES-SCLC patients. This study was aimed to evaluate the efficacy and safety of immunotherapy in combination with chemotherapy in elderly patients with ES-SCLC.

Methods: Elderly patients with ES-SCLC who were 70 years of age or older and were diagnosed at Shandong Cancer Hospital from May 20, 2020, to February 24, 2023, were included in this study. Overall survival (OS) and progression-free survival (PFS) were calculated via the Kaplan‒Meier method and compared via the log-rank test. In addition, the Cox regression model was used to analyze prognostic factors.

Results: A total of 135 patients were included in this study; 82 patients were in the immunotherapy combined with chemotherapy (IO + ChT) group, and 53 patients were in the chemotherapy alone (ChT-alone) group. The median overall survival (mOS) for the entire patient cohort was 12.89 months, whereas the median progression-free survival (mPFS) was 7.21 months. There was a significant difference in mPFS (8.26 months vs. 6.59 months, P =.02) and no statistically significant difference in mOS (14.20 months vs. 11.44 months, P =.14) between the IO + ChT and ChT-alone groups. The incidence of grade ≥ 3 adverse events in the IO + ChT group was not significantly different from that in the ChT-alone group. Moreover, we did not observe grade ≥ 3 immune-related adverse reactions. The univariate multifactorial analysis demonstrated that the absence of liver metastases at baseline and in female patients were favorable prognostic factors for OS, and the addition of immunotherapy was a favorable prognostic factor that improved overall survival in elderly patients with ES-SCLC. Subgroup analyses indicated that adding immunotherapy provided a survival benefit for patients with baseline brain metastases and baseline liver-free metastases.

Conclusion: Immunotherapy combined with chemotherapy can provide a survival benefit, and the addition of immunotherapy does not result in significant toxicity in elderly patients. The results of this study have important clinical implications for the future treatment of elderly patients with ES-SCLC.

References

Goldman J, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2020; 22(1):51-65. DOI: 10.1016/S1470-2045(20)30539-8. View

Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A . Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006; 24(28):4539-44. DOI: 10.1200/JCO.2005.04.4859. View

Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H . Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors. Cancer Med. 2024; 13(8):e7188. PMC: 11022147. DOI: 10.1002/cam4.7188. View

Ishii H, Azuma K, Shimose T, Yoshioka H, Kurata T, Shingu N . Phase II study of durvalumab (MEDI 4736) plus carboplatin and etoposide in elderly patients with extensive stage small cell lung cancer: Study protocol of turtle study (LOGIK 2003). Thorac Cancer. 2022; 14(1):105-107. PMC: 9807442. DOI: 10.1111/1759-7714.14727. View

Yu Y, Chen K, Fan Y . Extensive-stage small-cell lung cancer: Current management and future directions. Int J Cancer. 2022; 152(11):2243-2256. DOI: 10.1002/ijc.34346. View

Horn L, Mansfield A, Szczesna A, Havel L, Krzakowski M, Hochmair M . First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. View

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. View

Smith B, Smith G, Hurria A, Hortobagyi G, Buchholz T . Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17):2758-65. DOI: 10.1200/JCO.2008.20.8983. View

Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T . Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer. 2007; 97(2):162-9. PMC: 2360311. DOI: 10.1038/sj.bjc.6603810. View

10.

Balducci L, Ershler W . Cancer and ageing: a nexus at several levels. Nat Rev Cancer. 2005; 5(8):655-62. DOI: 10.1038/nrc1675. View

11.

Abdel-Rahman O . Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis. Clin Respir J. 2017; 12(3):1093-1099. DOI: 10.1111/crj.12632. View

12.

Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H . Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer. Cancer Med. 2022; 12(1):73-83. PMC: 9844637. DOI: 10.1002/cam4.4938. View

13.

Gore E, Hu C, Sun A, Grimm D, Ramalingam S, Dunlap N . Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937. J Thorac Oncol. 2017; 12(10):1561-1570. PMC: 5610652. DOI: 10.1016/j.jtho.2017.06.015. View

14.

Palma D, Warner A, Louie A, Senan S, Slotman B, Rodrigues G . Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis. Clin Lung Cancer. 2015; 17(4):239-44. DOI: 10.1016/j.cllc.2015.09.007. View

15.

Ma S, He Z, Liu Y, Wang L, Yang S, Wu Y . Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial. EClinicalMedicine. 2024; 70:102543. PMC: 10955204. DOI: 10.1016/j.eclinm.2024.102543. View

16.

Presley C, Gomes F, Burd C, Kanesvaran R, Wong M . Immunotherapy in Older Adults With Cancer. J Clin Oncol. 2021; 39(19):2115-2127. PMC: 8260908. DOI: 10.1200/JCO.21.00138. View

17.

Rudin C, Awad M, Navarro A, Gottfried M, Peters S, Csoszi T . Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21):2369-2379. PMC: 7474472. DOI: 10.1200/JCO.20.00793. View

18.

Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G . Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016; 7(33):53245-53253. PMC: 5288182. DOI: 10.18632/oncotarget.10644. View

19.

Lindblad K, Lujambio A . Liver metastases inhibit immunotherapy efficacy. Nat Med. 2021; 27(1):25-27. DOI: 10.1038/s41591-020-01190-9. View

20.

Yu J, Green M, Li S, Sun Y, Journey S, Choi J . Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021; 27(1):152-164. PMC: 8095049. DOI: 10.1038/s41591-020-1131-x. View